Industry Leaders

31. How To Prepare For The Next Healthcare Crisis That We Don't See Coming 7/1/2020

    Given everything that we have learned from the COVID-19 situation,  healthcare leaders can implement the following key takeaways to help them successfully weather the next storm that comes our way.

32. Building A Legacy With Complex Assets 6/1/2020

    For life science executives, deciding how to manage your overall portfolio, including illiquid or complex assets, is an important step in preserving both your financial and philanthropic legacies.

33. Do Biobanks Need New Strategies? 6/1/2020

    Precision medicine necessitates precision research, which necessitates getting highly specific biospecimens to researchers on demand, in alignment with their demand. Researchers shouldn’t have to adjust their research to whatever specimens are available; supply needs to fit the research.

34. How We Landed In The International Space Station 12/30/2019

    Looking back, it’s ironic that we named our company LaunchPad Medical. Our inspiration for the name came from our plan to take challenging ideas and materials and “launch” them into the medical space to revolutionize healthcare. But it never dawned on me to take our research to the International Space Station (ISS).

35. Taking A Strengths-Based Approach To Diversity & Inclusion 10/1/2019

    Organizations and their leaders often focus on what needs to improve, but research shows there is more to be gained from a strengths-based approach. Coaching around strengths yields greater optimism and success.

36. The Great Regulatory Catch-Up: Shortcuts To Compliance For Medical Devices Manufacturers 5/31/2019

    The medical device market is about to succumb to a raft of substantial international regulatory changes, starting with Europe’s MDR in May 2020, as public pressure and industry authorities call for greater accountability for patient safety.

37. 6 Tips For Contracting Or Seeking Funding From The Federal Government 5/31/2019

    With the right preparation and investments, entering the federal government market can lead to considerable growth and visibility for your company. Consider the following tips for increased chances of success.

38. A Different Path To An IPO 5/1/2019

    Typically, there are two paths biotechs take when going public — seeking VC funding or raising capital via a reverse merger. However, INmune Bio chose a third path.

39. Data Analytics Are Unlocking Valuable Cold-Chain Insights 5/1/2019

    Much like in many other areas of the drug development continuum, the focus now in the cold chain is on data and how it can be unlocked and analyzed in real time to save money, time, and resources — while also better ensuring patient safety.

40. Greater Rigor Is Needed To Enable Real-World Evidence To Reach Its Full Potential 5/1/2019

    As the industry’s appetite for creating and using data-driven insights to improve clinical outcomes continues to grow, so does the need to integrate and validate disparate data sources. Efforts to impose greater consistency and rigor should be welcomed by all.